In this video, Professor Christoph Correll defines the power, the sample size and effect size in clinical trials.

Published 20.05.2020
Permissions
Published 20.05.2020
Permissions

Related content

Article cover image showing blood samples and a hand description Article
Fluid biomarkers in Alzheimer’s disease: from detecting the pathology to understanding when it causes symptoms

Advances in blood biomarkers are transforming the diagnosis and prognosis of Alzheimer’s disease, helping to assess pathology, disease progression, and co-existing pathologies.

13.10.2026 Alzheimer’s Disease
image Image Diagram showing current and potential applications of blood-based biomarkers across the Alzheimer’s disease pathway
Current and potential applications for fluid biomarkers

Overview of how blood-based biomarkers may support screening, diagnosis, staging, prognosis, and treatment decisions across the Alzheimer’s disease continuum.

13.10.2026 Alzheimer’s Disease
image Image Flowchart illustrating a plasma biomarker testing protocol for symptomatic Alzheimer’s disease
A two-step blood-based algorithm

Overview of a plasma biomarker testing pathway for symptomatic Alzheimer’s disease, using p-tau217 and eMTBR-tau243 to guide diagnostic assessment and identify underlying pathology.

13.10.2026 Alzheimer’s Disease